Filing Details
- Accession Number:
- 0001209191-21-057414
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-23 16:19:14
- Reporting Period:
- 2021-09-21
- Accepted Time:
- 2021-09-23 16:19:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1808865 | Iteos Therapeutics Inc. | ITOS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1134657 | Luke Evnin | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1473930 | Todd Foley | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1609492 | Mpm Bioventures 2014, L.p. | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1609493 | Mpm Bioventures 2014 (B), L.p. | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1609495 | Mpm Asset Management Investors Bv2014 Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1729504 | Mpm Bioventures 2018 (B), L.p. | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1734817 | Mpm Asset Management Investors Bv2018 Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1765021 | Mpm Bioventures 2014 Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1765091 | Mpm Bioventures 2014 Gp Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-09-21 | 19,635 | $27.47 | 3,377,687 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2021-09-22 | 14,294 | $27.54 | 3,363,393 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
- The shares were sold as follows: 11,698 by MPM BioVentures 2014, L.P. ("BV 2014"), 403 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,388 by MPM BioVentures 2018, L.P. ("BV 2018") and 146 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 1,915,897 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 65,944 by AM BV2014, 1,210,040 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 23,880 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares were sold as follows: 8,516 by BV 2014, 293 by AM BV2014, 5,379 by BV 2018 and 106 by AM BV2018.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 to $27.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 1,907,381 by BV 2014, 107,713 by BV 2014(B), 65,651 by AM BV2014, 1,204,661 by BV 2018, 54,213 by BV 2018(B) and 23,774 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.